Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 4/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19420731 | 0.73 | CTDSP1 (0.98) | CTDSP1PABPC1TDP1APOBEC3AAPOBEC3G | |
| SCHEMBL28544297 | 0.73 | MEN1 (0.31) | KMT2A | |
| SCHEMBL9598615 | 0.73 | MEN1 (0.31) | CTDSP1KMT2A | |
| SCHEMBL9597774 | 0.73 | MEN1 (0.31) | CTDSP1KMT2A | |
| SCHEMBL1411292 | 0.73 | MEN1 (0.31) | CTDSP1KMT2A | |
| SCHEMBL19420724 | 0.72 | CTDSP1 (0.97) | CTDSP1PABPC1TDP1APOBEC3AAPOBEC3G | |
| SCHEMBL19420729 | 0.72 | CTDSP1 (0.97) | CTDSP1PABPC1TDP1APOBEC3AAPOBEC3G | |
| SCHEMBL8996657 | 0.72 | GAA (0.42) | KMT2A | |
| SCHEMBL8743017 | 0.71 | CA2 (0.36) | CTDSP1KMT2A | |
| SCHEMBL12708848 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283402-A1 | Poly(ADP-Ribose) Polymerase 1 Inhibitors Structurally Unrelated to NAD | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283402-A1 | Poly(ADP-Ribose) Polymerase 1 Inhibitors Structurally Unrelated to NAD | PARP1, PARP11, PARP14 | CTDSP1 242/4885PABPC1 434/4885TDP1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.